Official Title
Expanded Access to Navitoclax
Brief Summary

This is an expanded access program (EAP) for eligible participants. This program isdesigned to provide access to navitoclax prior to approval by the local regulatoryagency. Availability will depend on territory eligibility. A medical doctor must decidewhether the potential benefit outweighs the risk of receiving an investigational therapybased on the individual patient's medical history and program eligibility criteria.

No longer available
Individual Patients
Myelofibrosis
Acute Lymphocytic Leukemia (ALL)
Lymphoblastic Lymphoma

Drug: Navitoclax

Tablet, Oral
Other Name: ABT-263

Drug: Venetoclax

Tablet, Oral
Other Name: Venclexta,ABT-199,GDC-0199

Eligibility Gender
All
Eligibility Age
Minimum: 4 Years ~ Maximum: N/A
Countries
United States
Locations

Dana-Farber Cancer Institute /ID# 206198
Boston, Massachusetts, 02215

Available

ABBVIE INC.
Study Director
AbbVie

NCT Number
Keywords
Expanded Access
Pre-approval Access
Compassionate Use
Special Access Program
Named Patient Basis
Special Access Scheme
MeSH Terms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Venetoclax
Navitoclax